Hepatitis C virus replicons: potential role for drug development

Abstract

The development of causal therapies depends on the availability of systems to determine the inhibitory capacity of a compound. As viruses are obligate intracellular parasites, the efficacy of an antiviral drug is usually evaluated in a cell-culture system. Unfortunately, the hepatitis C virus, the principal causative agent of acute and chronic liver disease, cannot be propagated efficiently in the laboratory. However, the recent development of a replicon system opens up an encouraging possibility for drug discovery.

DOI: 10.1038/nrd942

Statistics

0102030'04'06'08'10'12'14'16
Citations per Year

99 Citations

Semantic Scholar estimates that this publication has 99 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Bartenschlager2002HepatitisCV, title={Hepatitis C virus replicons: potential role for drug development}, author={Ralf Bartenschlager}, journal={Nature Reviews Drug Discovery}, year={2002}, volume={1}, pages={911-916} }